ClinicalThought Commentary

Share

Program Content

Activities

  • FAQs on BCMA SLAMF7 in MM
    Experts Answer Questions About Therapies Targeting BCMA and SLAMF7 in Multiple Myeloma
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 20, 2023

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

cover img faculity

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Karyopharm Therapeutics, Legend Biotech USA Inc., and Pfizer Inc.

AbbVie Inc.

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics Inc.

Legend Biotech USA Inc.

Pfizer, Inc.